Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures: Is This All We Need to Know?
Authors: Heike A. Bischoff-Ferrari, Otto Meyer
Journal: Annals of Internal Medicine (2014)

Editorials18 November 2014Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures: Is This All We Need to Know?Heike A. Bischoff-Ferrari, MD, DrPH and Otto Meyer, MDHeike A. Bischoff-Ferrari, MD, DrPHFrom Geriatric Clinic, University Hospital Zurich, Centre on Aging and Mobility, University of Zurich, and City Hospital Waid, Zurich, Switzerland. and Otto Meyer, MDFrom Geriatric Clinic, University Hospital Zurich, Centre on Aging and Mobility, University of Zurich, and City Hospital Waid, Zurich, Switzerland.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-1942 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Nearly 75% of all osteoporotic fractures occur among adults aged 65 years or older, contributing significantly to illness and death in the senior population. After age 75 years, hip fractures are the most frequent, and severe fractures cause permanent functional impairment in 50%, loss of autonomy in 30%, and death in 15% to 20% of cases. The exponential increase in hip fractures after age 75 years translates into an estimated 1 in 3 women and 1 in 6 men who will have a hip fracture by their 90th year. Likewise, other osteoporotic fractures, including those of the spine, show a ...References1. Bischoff-Ferrari H. Fragility fractures: the future epidemic and its challenges. Skeletal Radiol. 2013;42:161-3. [PMID: 23188496] doi:10.1007/s00256-012-1549-4 CrossrefMedlineGoogle Scholar2. Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000;82-A:1063-70. [PMID: 10954094] CrossrefMedlineGoogle Scholar3. Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 1993;41:1226-34. [PMID: 8227898] CrossrefMedlineGoogle Scholar4. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-40. [PMID: 11172164] CrossrefMedlineGoogle Scholar5. Cummings SR, SanMartin J, McClung MR, Siris ES, Eastell R, Reid IR, et al; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65. [PMID: 19671655] doi:10.1056/NEJMoa0809493 CrossrefMedlineGoogle Scholar6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41. [PMID: 11346808] CrossrefMedlineGoogle Scholar7. Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96:1727-36. [PMID: 21411557] doi:10.1210/jc.2010-2784 CrossrefMedlineGoogle Scholar8. Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc. 2006;54:782-9. [PMID: 16696744] CrossrefMedlineGoogle Scholar9. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367:1714-23. [PMID: 23113482] doi:10.1056/NEJMoa1204061 CrossrefMedlineGoogle Scholar10. Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures. An updated systematic review. Ann Intern Med. 2014;161:711-23. doi:10.7326/M14-0317 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Geriatric Clinic, University Hospital Zurich, Centre on Aging and Mobility, University of Zurich, and City Hospital Waid, Zurich, Switzerland.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1942.Corresponding Author: Heike A. Bischoff-Ferrari, MD, DrPH, Geriatric Clinic, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland; e-mail, Heike.[email protected]ch.Current Author Addresses: Drs. Bischoff-Ferrari and Meyer: Geriatric Clinic, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.This article was published online first at www.annals.org on 9 September 2014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Effectiveness of Pharmacologic Treatments to Prevent Fractures Carolyn J. Crandall , Sydne J. Newberry , Allison Diamant , Yee-Wei Lim , Walid F. Gellad , Marika J. Booth , Aneesa Motala , and Paul G. Shekelle Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures Carolyn J. Crandall , Sydne J. Newberry , Allison Diamant , Yee-Wei Lim , Walid F. Gellad , Marika J. Booth , Aneesa Motala , and Paul G. Shekelle Metrics Cited ByA comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statementA comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statementA comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement 18 November 2014Volume 161, Issue 10Page: 755-756KeywordsClinical trialsElderlyFallsGeriatricsHip fracturesHospitalsMedical risk factorsOsteoporosisPatient advocacySystematic reviews ePublished: 18 November 2014 Issue Published: 18 November 2014 CopyrightCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...